The MHRA actively warns against purchasing and using unlicensed injectable medicines from unregulated online sources, citing risks of contamination, incorrect labelling, and unknown purity
As with all GLP-1 receptor agonists and incretin-based therapies, the most commonly reported adverse effects in the Phase 2 trial were gastrointestinal in nature
Do not attempt to obtain or use retatrutide from unregulated online sources, as product quality, safety, and dosing cannot be assured outside regulated supply
Semaglutide: Also effective, with many users losing 1015% or more of their body weight
TRANSCEND-T2D-1 Diabetes Trial TRANSCEND-T2D-1 was the first Phase 3 readout in type 2 diabetes, reported in March 2026 [8]
The one that fits YOUR health goals